Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Target Raised at Morgan Stanley

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target hoisted by Morgan Stanley from $20.00 to $22.00 in a report issued on Wednesday,Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.

A number of other brokerages have also commented on RARE. Canaccord Genuity Group increased their price target on Ultragenyx Pharmaceutical from $37.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, September 18th. Evercore cut Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 price target for the company. in a report on Thursday, September 3rd. Wedbush reduced their price objective on Ultragenyx Pharmaceutical from $25.00 to $22.00 and set a “neutral” rating on the stock in a research note on Wednesday. JPMorgan Chase & Co. cut Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $80.00 to $36.00 in a report on Thursday, September 3rd. Finally, HC Wainwright lowered their target price on Ultragenyx Pharmaceutical from $50.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $30.47.

Ultragenyx Pharmaceutical Price Performance

RARE stock opened at $17.16 on Wednesday. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -3.31 and a beta of 0.37. The business has a 50 day simple moving average of $16.45 and a two-hundred day simple moving average of $22.78. Ultragenyx Pharmaceutical has a 1-year low of $12.73 and a 1-year high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.06). The business had revenue of $173.00 million for the quarter, compared to the consensus estimate of $182.49 million. During the same quarter in the prior year, the company posted ($1.81) EPS. The business’s revenue was up 8.2% compared to the same quarter last year. Sell-side analysts anticipate that Ultragenyx Pharmaceutical will post -4.30 EPS for the current fiscal year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $15.27, for a total transaction of $107,897.82. Following the sale, the chief financial officer directly owned 89,229 shares in the company, valued at $1,362,526.83. This represents a 7.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 8,510 shares of company stock worth $127,561 over the last quarter. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors have recently modified their holdings of the stock. Versant Capital Management Inc increased its position in shares of Ultragenyx Pharmaceutical by 662.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,001 shares during the last quarter. GAMMA Investing LLC raised its holdings in Ultragenyx Pharmaceutical by 149.5% during the 2nd quarter. GAMMA Investing LLC now owns 1,919 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 1,150 shares during the period. Sterling Capital Management LLC raised its holdings in Ultragenyx Pharmaceutical by 102.4% during the 3rd quarter. Sterling Capital Management LLC now owns 2,475 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 1,252 shares during the period. Leonteq Securities AG raised its holdings in Ultragenyx Pharmaceutical by 288.5% during the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 1,333 shares during the period. Finally, Quantbot Technologies LP bought a new stake in Ultragenyx Pharmaceutical in the second quarter worth $48,000. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx reaffirmed its 2026 revenue and 2027 profitability outlook. It also said expense reductions are expected to cut 2027 R&D spending by at least 50% versus 2025, and it has agreements to sell two priority review vouchers for a combined $413 million. The company also reported FDA approval of GENGLYCOS and FAYUVI in the third quarter. Company earnings release
• Neutral Sentiment: Analyst actions were mixed. TD Cowen raised its target to $19 and kept a Buy rating; Canaccord cut its target to $34 but retained Buy. Morgan Stanley raised its target to $22 with an Equal Weight rating, while Goldman Sachs and Wedbush lowered targets to $17 and $22, respectively, and kept neutral ratings. Analyst ratings
• Negative Sentiment: Third-quarter revenue was $173 million, up 8.2% year over year but below the $182.49 million consensus. The $1.16-per-share loss also missed estimates of $1.10. A Seeking Alpha analysis additionally flagged reliance on CRYSVITA, limited contributions from newer launches, and pipeline setbacks; it argued the profitability pivot depends heavily on deep R&D cuts. Seeking Alpha analysis

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.